This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wire, M. B.
Right arrow Articles by Lewis, E. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wire, M. B.
Right arrow Articles by Lewis, E. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2007, p. 2982-2984, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00008-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged{triangledown}

Mary B. Wire,1* Charles H. Ballow,2 Julie Borland,1 Mark J. Shelton,1 Yu Lou,1 Geoffrey Yuen,1 Jiang Lin,1 and Eric W. Lewis1

GlaxoSmithKline, Research Triangle Park, North Carolina,1 Buffalo Clinical Research Center, Buffalo, New York2

Received 3 January 2007/ Returned for modification 2 March 2007/ Accepted 11 May 2007

Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this open-label study. The KETO area under the concentration-time curve at steady state was increased 2.69-fold with FPV/RTV. APV exposure was unchanged, and RTV exposure was slightly increased.

* Corresponding author. Mailing address: Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, 5 Moore Dr., 17.2231.2B, Research Triangle Park, NC 27709. Phone: (919) 483-5852. Fax: (919) 483-6380. E-mail: mary.b.wire{at}gsk.com

{triangledown} Published ahead of print on 21 May 2007.

Antimicrobial Agents and Chemotherapy, August 2007, p. 2982-2984, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00008-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»